

World Scleroderma Foundation (WSF) &  
Serbian and Romanian Societies of Pulmonology and Rheumatology

# e-MASTERCLASS

## on Systemic Sclerosis Interstitial Lung Disease (SSc-ILD)

A Collaborative Endeavor by  
the World Scleroderma Foundation and Serbian and  
Romanian Societies of Pulmonology and Rheumatology

**Friday, December 20, 2024**

09:00 - 17:30 (UTC + 1 - Italy and Serbia Time - Central European Time)

10:00 - 18:30 (UTC + 2 - Romania Time - Eastern European Time)

### SCIENTIFIC ORGANISERS:

Marco Matucci-Cerinic, Elena Rezus, Predrag Ostojic



## PROGRAMME

**09.00 Opening:** *M Matucci (WSF), E Rezus (SRR), P Ostojc (URS)*

**09.05 SESSION 1 - STATE OF THE ART LECTURES ON ILD SSC**

*Chairs: Predrag Ostojic*

**09:10** Pathophysiology of interstitial lung disease in SSc  
*Christopher Denton*

**09:30** IPF, so similar but so different from SSc  
*Dragos Bumbacea*

**09:50** Stratification and risk in SSc-ILD  
*Elena Rezus*

**10:10** Progression of Pulmonary Fibrosis in SSc: respirologist perspective  
*Claudia Toma*

**10:30** Six-minute-walk test and patient-reported outcome measures of ILD SSc to be used in practice  
*Bojana Stamenkovic*

**10:50 Survey Results & Discussion**

**10.50 SESSION 2 - DIAGNOSIS AND FOLLOW-UP OF PATIENTS WITH SSC-ILD**

*Chairs: Simona Rednic*

**10:55** The contribution of HRCT to the diagnosis and follow up of ILD SSc  
*Diana Manolescu*

**11:15** How to interpret in practice the modification of PFTs in CTD ILD  
*Sanja Dimic Janjic*

**11:35** How to implement the assessment of progression in SSc-ILD (incl future techniques)  
*Predrag Ostojic*

**11:55** Are BAL and lung biopsy necessary today in ILD?  
*Spasoje Popevic*

**12:15** Challenges of the group 3 Pulmonary Hypertension  
*Arsen Ristic*

**12:35 Survey Results & Discussion**

**12.35 Lunch Break**

**13.00 SESSION 3 - TREATMENT OF SSC-ILD**

*Chairs: Elena Rezus*

**13:05** Immunesuppressants, current practice, CYC, MMF Tocilizumab & RTX for SSc-ILD  
*Simona Rednic*

**13:25** Antifibrotic therapy for SSc ILD and the contribution of NTD  
*Magda Parvu*

**13:45** State of the art on recommendations for SSc management: 2023 EULAR update  
*Francesco Del Galdo*

**14:05** The management of SSc ILD: the ACR, EULAR and CTD-ILD ESR/EULAR recommendations  
*Yannick Allanore*

**14:25** Other treatment options  
*Marco Matucci Cerinic*

**14:45 Survey Results & Discussion**

**14.45 SESSION 4 - CURRENT PRACTICE OF MANAGEMENT OF SSC-ILD**

**14:45** Case I

*Mentor: Carina Mihai*

*Assistant: Ana Maria Gheorghiu*

**15:15** Case II

*Mentor: Simona Rednic*

*Assistant: Iulia Szabo*

**15:45 All faculty Q&A**

**16:10** Case III

*Mentor: Maja Zlatanovic*

*Assistant: Stretko Lukovic*

**16:30** Case IV

*Mentor: Jelena Colic*

*Assistant: Marina Vujovic*

**17:00 All faculty Q&A**

**17:15 Closure**

This activity has been accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC®).

Through an agreement between the European Board for Accreditation of Continuing Education for Health Professionals and the American Medical Association physicians may convert EBAC® CE credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC credit to AMA credit can be found on the AMA website. Other health care professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 1 Credit™.